Xigduo XR 5 mg/500 mg BID is the equivalent dose to Synjardy 5 mg/500 mg BID
The direct equivalent of Synjardy 5 mg/500 mg BID is Xigduo XR 5 mg/500 mg BID 1, 2. Both formulations contain 500 mg metformin and 5 mg of their respective SGLT2 inhibitor (empagliflozin in Synjardy, dapagliflozin in Xigduo), making them pharmacologically comparable for twice-daily dosing.
Key Dosing Considerations
Component Equivalence
- SGLT2 inhibitor component: Both empagliflozin 5 mg and dapagliflozin 5 mg are low-dose SGLT2 inhibitors with similar glucose-lowering efficacy 1, 2
- Metformin component: Both contain identical 500 mg metformin HCl doses 1, 2
- Dosing frequency: Both can be administered twice daily with meals 1, 2
Important Clinical Differences
While the doses are equivalent, there are subtle efficacy differences:
Empagliflozin (Synjardy) may offer slightly superior glycemic control. In a 52-week head-to-head trial, empagliflozin 25 mg demonstrated greater HbA1c reduction compared to dapagliflozin 10 mg when added to triple therapy (P < 0.001), along with better improvements in HDL cholesterol 3. However, this study used higher doses than the 5 mg formulations being compared.
Both SGLT2 inhibitors provide cardiovascular and renal benefits as outlined in current ADA guidelines, with proven reduction in MACE and heart failure hospitalizations 4. The guideline emphasizes that SGLT2 inhibitors should be continued for cardiovascular and kidney benefit even when eGFR falls below 45 mL/min/1.73 m², despite minimal glucose-lowering effect at that level 4.
Renal Function Considerations
Critical dosing restrictions apply based on kidney function 1, 2:
- Do not initiate either combination if eGFR < 45 mL/min/1.73 m² (due to metformin component)
- Contraindicated if eGFR < 30 mL/min/1.73 m² (severe renal impairment)
- Once established on therapy, SGLT2 inhibitors can be continued for cardiovascular/renal benefit until dialysis, even as eGFR declines 4
Safety Profile Commonalities
Both combinations share similar adverse effect profiles 1, 2:
- Genital mycotic infections: Mitigate with proper hygiene counseling
- Volume depletion: Monitor blood pressure and adjust diuretics as needed
- DKA risk: Rare in T2DM but provide sick-day planning; discontinue 3-4 days before surgery
- Metformin-related: GI side effects (take with food), vitamin B12 deficiency (monitor), lactic acidosis risk (avoid in hepatic impairment)
The practical conversion is straightforward: Xigduo XR 5 mg/500 mg BID directly replaces Synjardy 5 mg/500 mg BID with equivalent dosing and similar clinical outcomes.